RNA aptamer-mediated RNA nanotechnology for potential treatment of cardiopulmonary diseases

IF 9.1 2区医学 Q1 PHARMACOLOGY & PHARMACY

Pharmacological research Pub Date : 2025-02-18 DOI:10.1016/j.phrs.2025.107659

Boyu Xia , Nargis Shaheen , Huilong Chen , Jing Zhao , Peixuan Guo , Yutong Zhao

{"title":"RNA aptamer-mediated RNA nanotechnology for potential treatment of cardiopulmonary diseases","authors":"Boyu Xia , Nargis Shaheen , Huilong Chen , Jing Zhao , Peixuan Guo , Yutong Zhao","doi":"10.1016/j.phrs.2025.107659","DOIUrl":null,"url":null,"abstract":"<div><div>Ribonucleic acid (RNA) aptamers are single-stranded RNAs that bind to target proteins or other molecules with high specificity and affinity, modulating biological functions through distinct mechanisms. These aptamers can act n as antagonists to block pathological interactions, agonists to activate signaling pathways, or delivery vehicles for therapeutic cargos such as siRNAs and miRNAs. The advances in RNA nanotechnology further enhances the versatility of RNA aptamers, offering scalable platforms for engineering. In this review, we have summarized recent developments in RNA aptamer-mediated RNA nanotechnology and provide an overview of its potential in treating cardiovascular and respiratory disorders, including atherosclerosis, acute coronary syndromes, heart failure, lung cancer, pulmonary hypertension, asthma, chronic obstructive pulmonary disease (COPD), acute lung injury, viral respiratory infections, and pulmonary fibrosis. By integrating aptamer technologies with innovative delivery systems, RNA aptamers hold the potential to revolutionize the treatment landscape for cardiopulmonary diseases.</div></div>","PeriodicalId":19918,"journal":{"name":"Pharmacological research","volume":"213 ","pages":"Article 107659"},"PeriodicalIF":9.1000,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacological research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1043661825000842","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Ribonucleic acid (RNA) aptamers are single-stranded RNAs that bind to target proteins or other molecules with high specificity and affinity, modulating biological functions through distinct mechanisms. These aptamers can act n as antagonists to block pathological interactions, agonists to activate signaling pathways, or delivery vehicles for therapeutic cargos such as siRNAs and miRNAs. The advances in RNA nanotechnology further enhances the versatility of RNA aptamers, offering scalable platforms for engineering. In this review, we have summarized recent developments in RNA aptamer-mediated RNA nanotechnology and provide an overview of its potential in treating cardiovascular and respiratory disorders, including atherosclerosis, acute coronary syndromes, heart failure, lung cancer, pulmonary hypertension, asthma, chronic obstructive pulmonary disease (COPD), acute lung injury, viral respiratory infections, and pulmonary fibrosis. By integrating aptamer technologies with innovative delivery systems, RNA aptamers hold the potential to revolutionize the treatment landscape for cardiopulmonary diseases.

查看原文本刊更多论文

RNA适体介导的RNA纳米技术用于心肺疾病的潜在治疗

核糖核酸（RNA）适体是一种单链RNA，具有高特异性和亲和力结合靶蛋白或其他分子，通过不同的机制调节生物功能。这些适体可以作为阻断病理相互作用的拮抗剂，激活信号通路的激动剂，或作为sirna和mirna等治疗物质的递送载体。RNA纳米技术的进步进一步增强了RNA适体的多功能性，为工程提供了可扩展的平台。在这篇综述中，我们总结了RNA适配体介导的RNA纳米技术的最新进展，并概述了其在治疗心血管和呼吸系统疾病方面的潜力，包括动脉粥样硬化、急性冠状动脉综合征、心力衰竭、肺癌、肺动脉高压、哮喘、慢性阻塞性肺疾病（COPD）、急性肺损伤、病毒性呼吸道感染和肺纤维化。通过将适体技术与创新的递送系统相结合，RNA适体具有彻底改变心肺疾病治疗前景的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pharmacological research 医学-药学

CiteScore

18.70

自引率

3.20%

发文量

491

审稿时长

8 days

期刊介绍： Pharmacological Research publishes cutting-edge articles in biomedical sciences to cover a broad range of topics that move the pharmacological field forward. Pharmacological research publishes articles on molecular, biochemical, translational, and clinical research (including clinical trials); it is proud of its rapid publication of accepted papers that comprises a dedicated, fast acceptance and publication track for high profile articles.